About the Company

EPIRUS Biopharmaceuticals, Inc. (NasdaqCM: EPRS) is a biopharmaceutical company focused on the development, production, and commercialization of biosimilar products for major markets such as the US and Europe, as well as additional targeted global markets. The Company has a strategy in place to address the regulatory and commercial landscape of each market. EPIRUS recently launched its lead biosimilar candidate BOW015 in India under the brand name Infimabâ„¢. BOW015 has been extensively characterized and the Company has produced a robust data package supportive of biosimilarity to Remicade (infliximab). Additional programs are underway to create biosimilars to Humira and Actemra, two monoclonal antibodies indicated for the treatment of inflammatory diseases. EPIRUS is on track to submit regulatory applications for BOW015 in the US and EU in 2017.

Source: LifeSci Capital, LLC research report

Research analyst certification and important disclosures can be found in the full research report. To access the full research report, please click on the link below.

Recent Research